NCT07102719View on ClinicalTrials.gov

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

HD-P023

Single dose administration of HD-P023

DRUG

Teneligliptin and Empagliflozin

Single does administration of Teneligliptin and Empagliflozin High

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

Sponsors

Lead Sponsor

Handok Inc.
All Listed Sponsors
lead

Handok Inc.

INDUSTRY

NCT07102719 - Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers | Biotech Hunter | Biotech Hunter